Trials / Completed
CompletedNCT01811472
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine whether LCQ908 effectively lowers liver fat, as assessed by MRI and to assess its safety and tolerability profile in subjects with non-alcoholic fatty liver disease (NAFLD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LCQ908 | LCQ908 5 mg, 10 mg, 20 mg tablets |
| DRUG | placebo | Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets. |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2013-03-14
- Last updated
- 2016-02-04
- Results posted
- 2016-02-04
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01811472. Inclusion in this directory is not an endorsement.